News
6th pilot rapid assessment of WP5 JA2 Strand B on “Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke”
The purpose of the assessment is to examine the effectiveness and safety of mechanical thrombectomy in adults aged 18 years or older with acute ischaemic
4th pilot rapid assessment of WP5 JA2 Strand B on “Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenosis”
The purpose of the assessment is to address the research question whether the use of biodegradable stents for benign refractory or recurrent oesophageal stenosis is
3rd Pilot rapid assessment on ‘Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction’
The purpose of the assessment is to evaluate the use of Balloon Eustachian Tuboplasty (BET) for Eustachian tube dysfunction (ETD) in a population aged over
At a glance: EUnetHTA JA2 Year 2
Looking forward to a productive and successful 2015, EUnetHTA is happy to update on some of the accomplishments of 2014 (Second year of JA2). Overall
Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer. Final version of the assessment
Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine
The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma Final version of the assessment was published
The methodological guideline on “Meta-analysis of diagnostic test accuracy studies” now available
The methodological guideline on “Meta-analysis of diagnostic test accuracy studies” has been finalised after its public consultation phase and is now available. It was developed
HTA as a health policy tool in the Council’s conclusions on innovation for the benefit of the patient
Significance of HTA and the HTA Network Strategy are highlighted in the conclusions on innovation for the benefit of the patient adopted by the Council
All material and documents from the HTA 2.0 Europe conference is now available
The HTA 2.0 Europe – Teaming Up for Value conference took place in Rome, Italy on 30-31 October 2014. All important and relevant material from
[CLOSED] Public consultation of the draft methodological guideline “Methods for health economic evaluations”
We are pleased to announce that as of today, 18 November 2014, the draft methodological guideline “Methods for health economic evaluations”, produced within Subgroup 3
